Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Caspofungin vs Liposomal Amphotericin B vs Combination in Post-Transplant Patients
NCT00148148Phase 2Completed
- Sponsor
- Universitätsklinikum Münster
- Start
- May 2004
- Modality
- Cyclic Peptides, Lipid-based Nanoparticles, Antimicrobial Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of caspofungin and liposomal amphotericin b in invasive fungal infection (IFI) (3 arms), sponsored by Universitätsklinikum Münster. Primary endpoint: Safety and efficacy of caspofungin, liposomal amphotericin B and the combination. Started May 2004; status: completed.
02
Drugs
caspofunginliposomal amphotericin b
03
Conditions
invasive fungal infection (IFI)
Beyond the preview
Go deeper on NCT00148148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00148148.